Tirzepatide Once Weekly for the Treatment of Obesity
Authors: Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al.
Journal
N Engl J Med
Year
2022
Citations
600
Type
Clinical Trial
Subject
Human
Condition
Obesity / Type 2 Diabetes
TL;DR
SURMOUNT-1: In 2,539 adults with obesity, once-weekly tirzepatide (GIP/GLP-1 dual agonist) achieved substantial sustained weight loss over 72 weeks.
View Paper
DOI: 10.1056/NEJMoa2206038
Abstract
Obesity is a chronic disease that results in substantial global morbidity and mortality.. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known.. In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in.